Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline M Moore

Showing results (131-140 of 231) with videos related to

Pageof 24
Sort By:
The British Journal of Radiology|September 21, 2020
Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISEFrancesco Giganti, Vasilis Stavrinides, Armando Stabile, et al.
The Journal of Urology|October 16, 2012
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancerVeeru Kasivisvanathan, Robert Dufour, Caroline M Moore, et al.
European Urology|May 4, 2020
Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort StudyVasilis Stavrinides, Francesco Giganti, Bruce Trock, et al.
International Urology and Nephrology|September 9, 2025
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024)Boyuan Xiao, Zhiyu Qian, Andrea Piccolini, et al.
European Radiology|May 20, 2017
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trialFrancesco Giganti, Caroline M Moore, Nicola L Robertson, et al.
European Urology Open Science|March 3, 2025
Applying Focal Therapy to Lesions Detected via Magnetic Resonance Imaging: Delivering Cancer Ablation Beyond the Visibility PhenomenonClement Orczyk, Teresa Marsden, Francesco Giganti, et al.
Plos One|February 24, 2022
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analysesTeresa Marsden, Neil McCartan, Louise Brown, et al.
BJU International|May 21, 2014
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapyCaroline M Moore, Abel-Rahmene Azzouzi, Eric Barret, et al.
European Urology|May 24, 2020
The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional SeriesArmando Stabile, Clement Orczyk, Francesco Giganti, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 15, 2017
Prostate cancer detection using quantitative T<sub>2</sub> and T<sub>2</sub> -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillanceFrancesco Giganti, Giulio Gambarota, Caroline M Moore, et al.
Pageof 24

Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
The British Journal of Radiology|September 21, 2020
Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISEFrancesco Giganti, Vasilis Stavrinides, Armando Stabile, et al.
The Journal of Urology|October 16, 2012
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancerVeeru Kasivisvanathan, Robert Dufour, Caroline M Moore, et al.
European Urology|May 4, 2020
Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort StudyVasilis Stavrinides, Francesco Giganti, Bruce Trock, et al.
International Urology and Nephrology|September 9, 2025
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024)Boyuan Xiao, Zhiyu Qian, Andrea Piccolini, et al.
European Radiology|May 20, 2017
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trialFrancesco Giganti, Caroline M Moore, Nicola L Robertson, et al.
European Urology Open Science|March 3, 2025
Applying Focal Therapy to Lesions Detected via Magnetic Resonance Imaging: Delivering Cancer Ablation Beyond the Visibility PhenomenonClement Orczyk, Teresa Marsden, Francesco Giganti, et al.
Plos One|February 24, 2022
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analysesTeresa Marsden, Neil McCartan, Louise Brown, et al.
BJU International|May 21, 2014
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapyCaroline M Moore, Abel-Rahmene Azzouzi, Eric Barret, et al.
European Urology|May 24, 2020
The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional SeriesArmando Stabile, Clement Orczyk, Francesco Giganti, et al.
Journal of Magnetic Resonance Imaging : JMRI|November 15, 2017
Prostate cancer detection using quantitative T<sub>2</sub> and T<sub>2</sub> -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillanceFrancesco Giganti, Giulio Gambarota, Caroline M Moore, et al.
Pageof 24